Institute of Integrative Omics and Applied Biotechnology

IIOAB

  PRESS RELEASE

IIOAB, India: 26th Oct, 2015

 Novel association between obesity and diabetes through miRNA is identified

 

In today’s bio-medical research microRNA (miRNAs) are getting increasing importance for their various roles in human patho-physiologies. However, an integrated resource on how the miRNA regulates (miRNA regulome) such biological events are not available.

An international team of scientists led by Dr. Debmalya Barh from the Institute of Integrative Omics and Applied Biotechnology (IIOAB), Purba Medinipur, WB, India has developed the miRegulome- a unique knowledge-base of miRNA regulomics and analysis that provides a single window for a wide range of data exploration, visualization of miRNA regulome and data interpretation, exploration of new biological events, and biomarker discovery using its integrated highly efficient of tools ad search engines.

Using the miRegulome v1.0, these researchers are able to identify a novel relationship between obesity and diabetes. It is found that deregulation of mir-27b and mir-143 may affect lipid metabolism, adipocytokine, insulin, and type-2 diabetes pathways and eventually may lead to develop obesity and diabetes. Further, an aberrant expression of mir-27b may play a role in obesity-associated insulin resistance by modulating adipocytokines and Ribavirin resistance in obese patients thus linking obesity with diabetes at a new and deeper molecular level.

Dr. Preetam Ghosh form Dept. of Computer Science, Virginia Commonwealth University, USA, who headed the computing part, describes miRegulome as a powerful tool and according Dr. Barh it will be an essential resource in miRNOmics R&D in coming days.  

The work is published recently in Nature Scientific Reports: http://www.nature.com/articles/srep12832

________________________

Institute of Integrative Omics and Applied Biotechnology (IIOAB)

Nonakuri, Purba Medinipur, West Bengal-721172; India

Email: info.iioab@gmail.com

Web: www.iioab.webs.com

 ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

PRESS RELEASE

IIOAB, India: 5th Dec, 2014

 

Limca Book of Records recognizes IIOAB for its cutting-edge research without fund and infrastructure

 

Scientific research to address various global issues related to the bio-medical, agricultural, and environmental sciences require significant funding and infrastructural support. However, a true passion for science coupled with strong determination, well thought out strategies, and unique management and leadership skills can bypass the need of such conventional requirements.   

Limca Book of Records (LBR), the “Indian equivalent to the Guinness Book of World Records” has identified and recognized the Institute of Integrative Omics and Applied Biotechnology (IIOAB) and its founder Debmalya Barh for such a unique achievement that was featured in the Education Section of the recently published 25th anniversary edition of LBR.

IIOAB is a first-of-its-kind virtual multidisciplinary research organization in India that was registered in 2008 at Nonakuri, Purba Medinipur, WB. Barh’s innovative strategies brought together more than 400 eminent researchers from nearly 100 top institutes across 35-40 countries to address various bio-medical, agricultural, and environmental issues with global impacts including cancer, neurosciences, metabolic disorders, infectious diseases, renewable energy etc, without using any funding support or infrastructure. The research outcomes of IIOAB are comparable to any sponsored research institute having state-of-the-art infrastructures, generous funding support, and significant human resources. The organization is now well-known to the global scientific communities.

“IIOAB and Debmalya’s working strategies are path breaking and an inspiration to researchers across the world; I am proud to be associated with IIOAB” said Prof. Preetam Ghosh from Virginia Commonwealth University, USA. Prof. Kenneth Blum of College of Medicine, University of Florida who is also widely regarded as the father of psychiatric genetics explains why Debmalya deserves such a great honour. According to him, “key behind the success is his strong determination, leadership skills, and strategic management abilities”. Prof. Vasco Azevedo from UFMG, Brazil and Prof. Anil Kumar, HOD, Biotechnology, Devi Ahilya University, India request Govt. and Private sectors to support the initiatives of IIOAB for its future development and accomplishing its ambitious research mission to serve science and mankind.

_________________________________________

Institute of Integrative Omics and Applied Biotechnology (IIOAB)

Nonakuri, Purba Medinipur, West Bengal-721172; India

Email: info.iioab@gmail.com

Web: www.iioab.webs.com

 ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

PRESS RELEASE

IIOAB, India: 8th Nov, 2013

 

Simple blood test for sub-type specific lung cancer diagnosis

 

Lung cancer is the leading cause of cancer specific death worldwide. 85% lung cancers are non-small cell lung cancers (NSCLC) while remaining are small cell lung cancers (SCLC). Although X-Ray and CT scan remain the main non-invasive diagnosis strategy, the painful lung tissue biopsy is essential for confirmation and staging of the disease.    

An international team of researchers from India, UK, Spain, Brazil, and the USA led by Debmalya Barh from the Institute of Integrative Omics and Applied Biotechnology (IIOAB) in Nonakuri, Tamluk, Purba Medinipur, West Bengal, India have identified blood based novel diagnostic markers those can be useful in early detecting the lung cancer and even their sub-typing i.e. whether its SCLC or NSCLC.

The researches have used a novel reverse-transcriptomics strategy to identify the biomarkers. The findings suggest that in a simple PCR based test if HMGA1, E2F6, IRF1, and TFDP1 are expressed and SUV39H1, RBL1, and HNRPD do not express in blood, the patient is having lung adenocarcinoma and/or squamous cell carcinoma sub-types of NSCLC.

Dr. Elena Padin-Iruegas form Medical Oncology Department, Complejo Hospitalario Universitario, Spain, who is associated with this research, says that “the identified markers are gold standard” and according Debmalya Barh who led the research “The novel reverse-transcriptomics-based integrated approach developed in this work can be applicable to identify early biomarkers not only for the lung cancer but can be applicable to other cancers and diseases too”.

The study has been recently published in BMC Genomics 14 (Suppl 6), S5, 28 Oct, 2013

__________________________________________

Institute of Integrative Omics and Applied Biotechnology (IIOAB) 

Nonakuri, Tamluk, Purba Medinipur, West Bengal-721172; India

Email: info.iioab@gmail.com

Web: www.iioab.webs.com 

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

 

PRESS RELEASE

IIOAB India 
31st Jan, 2013

 

 

Discovery of anti- Tuberculosis, Plague, Diphtheria, Diarrhea, and Cholera drugs from Piper betle (Paan)

 _________________________________________________________________________________________________________________

The Betel vine leaf (Piper betle of Piperaceae family) is commonly known as Paan and it is one of the economic crops of several south Asian countries and the West Bengal State of India. Pann is generally consumed after food as a chewing preparation and mouth freshener in combination with slaked lime paste, areca nut, and sometimes with tobacco. In Puja and various Vedic rituals Paan is an essential element and in Ayurvedic medicine, it’s used to treat various diseases including headaches, respiratory problems, constipation, inflammation, and wounds among others. However, the active compounds of Paan that are having such medicinal properties are not yet known.

 

Researchers leaded by Debmalya Barh from Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Tamluk, Purba Medinipur, West Bengal, India (www.iioab.webs.com) in collaboration with researchers from Mexico, Brazil, USA, Denmark and three Indian Institutes have first time identified compounds from Betel leaves (which is an economic crop of IIOAB’s locality) that are useful in developing broad spectrum antibiotics against  Caseous Lymphadenitis (in cattle), Diphtheria, Tuberculosis, Plague, Hemorrhagic diarrhea, and Cholera.

 

The groups leaded by Debmalya Barh have recently published their novel findings in two highly reputed Journals (1) Integrative Biology (published on 03rdJan, 2013) and in (2) PLOS ONE (published on 30th Jan, 2013).

 

In these works they have identified a novel target common to pathogens causing Caseous Lymphadenitis (in cattle), Diphtheria, Tuberculosis, Plague, Hemorrhagic diarrhea and three novel targets common to all pathogenic Vibrio cholerae strains.

 

Further, first time these researchers have also identified specific Piper betle derived compounds that can render the activities of these novel targets killing the pathogen. In addition, they have also shown that these Piper betle compounds are highly effective and have better efficacy than currently used drugs against these pathogens.

 

Identification of these novel targets and targeting compounds is the first step towards developing novel targeted drugs from Piper betle to tackle these infectious diseases. Currently, these researchers are extensively working to increase the efficacy of these compounds against all these pathogens using in silico, in vitro and in vivo systems. Barh and his colleagues are confident that, they will be able to establish Piper betel shortly as a source of next-generation drugs to cope with Diphtheria, Tuberculosis, Plague, hemorrhagic diarrhea, and Cholera like deadly infectious diseases.

 

The Integrative Biology, article published on 03rdJan, 2013 can be accessed from:

http://pubs.rsc.org/En/content/articlelanding/2012/ib/c2ib20206a

The PLOS ONE article published on 30th Jan, 2013 can be accessed from:

http://dx.plos.org/10.1371/journal.pone.0052773

 

_________________________________________________________________________________________________________________

About IIOAB

The Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur, West Bengal, India (www.iioab.webs.com) is a non-Govt. Scientific Organization that aims to (1) provide a global platform for multidisciplinary research and advocacy to combat various global challenges; (2) to promote of higher education, R&D, traditional knowledge, grassroots innovations, and IPR; human resource and rural development; and (3) to serve science, mankind, society, and the Nation. IIOAB works in the field of highly demanding and challenging areas of biology having global insist in collaboration with more than to 200 researchers worldwide. It works towards integrative omics based translational researches, target and targeted drug discovery, early diagnostic biomarkers, pharmacogenomics, neutrigenomics, cancer, neuroscience, CVDs, infectious, and metabolic diseases, and plant, animal, and environmental biotechnology.

Institute of Integrative Omics and Applied Biotechnology (IIOAB)
Nonakuri, Tamluk, Purba Medinipur, West Bengal-721172; India 
Web: www.iioab.webs.com ; Email: info.iioab@gmail.com

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

India- Oct 8th,2011

 

The Academic and R&D website of Institute of Integrative Omics and Applied Biotechnology (IIOAB) (www.iioab.ac.in) was inaugurated by Prof. Soumen Kumar Mahapatra, H'ble Minister, Govt. Of West Bengal on 8th Oct, 2011 at Nonakuri, Purba Medinipur, WB, India.

 

About IIOAB

 

The institute currently runs as a virtual research institute and probably the first of its kind in West Bengal as well as in India that aims to provide a global platform for multidisciplinary research and advocacy by collaborative inter-disciplinary R&D to combat global threats of 21st century. Presently, all works are coordinated from Bangalore. 

 

The institute works in collaboration with more than 20 top international research groups consisting of more than 40 scientists from USA, UK, Brazil, like 10-12 countries and is having Advisors/Mentors from MIT, Oxford, Imperial College of London like top 10 institutes of the world. Several pioneer and leading scientists are associated with the organization.

 

The institute works towards integrative omics based next-generation non-invasive early biomarker discovery and development of personalized medicine and nutraceuticle for cancers, CVDs, metabolic disorders, and neuropsychiatric diseases etc. It also works on next-generation drug and vaccine designing for infectious and STDs. Apart from these, other focused areas are bioprocessing, agri-biotechnology, biofortification, renewable energy, agricultural and environmental sustainability, rural development, promotion of higher education, traditional knowledge, grassroots innovations etc.

 

So far IIOAB has published several researches in top ranked journals and has presented research papers in many international conferences. Several works are pioneer such as molecular diagnosis and drug targets in male breast cancer and cardiac myxoma, new drug and vaccine targets in gonorrhea, and genome sequencing and target identification in cattle and human pathogens etc. To promote R&D, the institute also publishes research reference books and has introduced two international journals having world class editorial board.

 

Most importantly, the institute runs on voluntary services and with out any fund. The organization looks for financial supports and donation to setup all laboratories.